Literature DB >> 9632626

Nonspecific early protective immunity in Francisella and Listeria infections can be dependent on lymphocytes.

K L Elkins1, A T MacIntyre, T R Rhinehart-Jones.   

Abstract

Normal mice, but not lymphocyte-deficient or B-cell-deficient mice, given a sublethal infection of Francisella tularensis LVS survive a secondary lethal challenge of more than 10,000 50% lethal doses given 3 days later. In this work, we show that similar early protection that is also strongly lymphocyte dependent operates in Listeria monocytogenes infection. Since sublethal infection with either LVS or L. monocytogenes protects against heterologous lethal challenge, this early protection is nonspecific.

Entities:  

Mesh:

Year:  1998        PMID: 9632626      PMCID: PMC108373     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  13 in total

1.  Loss of either CD4+ or CD8+ T cells does not affect the magnitude of protective immunity to an intracellular pathogen, Francisella tularensis strain LVS.

Authors:  D Yee; T R Rhinehart-Jones; K L Elkins
Journal:  J Immunol       Date:  1996-12-01       Impact factor: 5.422

2.  A novel role for B cells in early protective immunity to an intracellular pathogen, Francisella tularensis strain LVS.

Authors:  S J Culkin; T Rhinehart-Jones; K L Elkins
Journal:  J Immunol       Date:  1997-04-01       Impact factor: 5.422

3.  Live tularemia vaccine but not proteins purified from Francisella tularensis can confer protection against lethal Listeria infection in mice.

Authors:  Y F Belyi; V V Petrosov; I S Tartakovskii; Y G Suchkov
Journal:  APMIS       Date:  1995-02       Impact factor: 3.205

4.  Inability of the Francisella tularensis lipopolysaccharide to mimic or to antagonize the induction of cell activation by endotoxins.

Authors:  P Ancuta; T Pedron; R Girard; G Sandström; R Chaby
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

5.  Rapid generation of specific protective immunity to Francisella tularensis.

Authors:  K L Elkins; D A Leiby; R K Winegar; C A Nacy; A H Fortier
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

6.  Early pathogenesis of infection in the liver with the facultative intracellular bacteria Listeria monocytogenes, Francisella tularensis, and Salmonella typhimurium involves lysis of infected hepatocytes by leukocytes.

Authors:  J W Conlan; R J North
Journal:  Infect Immun       Date:  1992-12       Impact factor: 3.441

7.  Studies with MHC-deficient knock-out mice reveal impact of both MHC I- and MHC II-dependent T cell responses on Listeria monocytogenes infection.

Authors:  C H Ladel; I E Flesch; J Arnoldi; S H Kaufmann
Journal:  J Immunol       Date:  1994-10-01       Impact factor: 5.422

8.  Introduction of Francisella tularensis at skin sites induces resistance to infection and generation of protective immunity.

Authors:  K L Elkins; R K Winegar; C A Nacy; A H Fortier
Journal:  Microb Pathog       Date:  1992-11       Impact factor: 3.738

9.  Immunity to Salmonella typhimurium infection in C3H/HeJ and C3H/HeNCrlBR mice: studies with an aromatic-dependent live S. typhimurium strain as a vaccine.

Authors:  L M Killar; T K Eisenstein
Journal:  Infect Immun       Date:  1985-03       Impact factor: 3.441

10.  Immunogenicity and toxicity of lipopolysaccharide from Francisella tularensis LVS.

Authors:  G Sandström; A Sjöstedt; T Johansson; K Kuoppa; J C Williams
Journal:  FEMS Microbiol Immunol       Date:  1992-10
View more
  9 in total

Review 1.  Antibody-independent functions of B cells: a focus on cytokines.

Authors:  Ping Shen; Simon Fillatreau
Journal:  Nat Rev Immunol       Date:  2015-06-12       Impact factor: 53.106

2.  Importance of B cells, but not specific antibodies, in primary and secondary protective immunity to the intracellular bacterium Francisella tularensis live vaccine strain.

Authors:  K L Elkins; C M Bosio; T R Rhinehart-Jones
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

3.  Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon.

Authors:  V C Dreisbach; S Cowley; K L Elkins
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

4.  B1a cells enhance susceptibility to infection with virulent Francisella tularensis via modulation of NK/NKT cell responses.

Authors:  Deborah D Crane; Amanda J Griffin; Tara D Wehrly; Catharine M Bosio
Journal:  J Immunol       Date:  2013-02-01       Impact factor: 5.422

5.  Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized Type A F. tularensis.

Authors:  Qingmei Jia; Bai-Yu Lee; Daniel L Clemens; Richard A Bowen; Marcus A Horwitz
Journal:  Vaccine       Date:  2009-01-04       Impact factor: 3.641

6.  Intranasal vaccination with a defined attenuated Francisella novicida strain induces gamma interferon-dependent antibody-mediated protection against tularemia.

Authors:  Michael A Pammit; Erin K Raulie; Crystal M Lauriano; Karl E Klose; Bernard P Arulanandam
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

7.  YopP-expressing variant of Y. pestis activates a potent innate immune response affording cross-protection against yersiniosis and tularemia [corrected].

Authors:  Ayelet Zauberman; Yehuda Flashner; Yinon Levy; Yaron Vagima; Avital Tidhar; Ofer Cohen; Erez Bar-Haim; David Gur; Moshe Aftalion; Gideon Halperin; Avigdor Shafferman; Emanuelle Mamroud
Journal:  PLoS One       Date:  2013-12-16       Impact factor: 3.240

8.  Early infection-induced natural antibody response.

Authors:  Klara Kubelkova; Tomas Hudcovic; Hana Kozakova; Jaroslav Pejchal; Ales Macela
Journal:  Sci Rep       Date:  2021-01-15       Impact factor: 4.379

9.  Impaired antibacterial host defense in mice lacking the N-formylpeptide receptor.

Authors:  J L Gao; E J Lee; P M Murphy
Journal:  J Exp Med       Date:  1999-02-15       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.